# Clinical Trials Data KRAS - Document 12

# Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

## Clinical Trial: https://clinicaltrials.gov/study/NCT01933932

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Provision of signed, written and dated informed consent prior to any study specific procedures\n\* Male or female, aged 18 years or older\n\* Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)\n\* KRAS mutation positive tumour sample as determined by the designated testing laboratory\n\* Failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy\n\nExclusion Criteria:\n\n\* Mixed small cell and non-small cell lung cancer histology.\n\* Received \\>1 prior anti-cancer drug regimen for advanced or metastatic NSCLC. Patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.\n\* Receiving or have received systemic anti-cancer therapy within 30 days prior to starting study treatment\n\* Other concomitant anti-cancer therapy agents excepts steroids\n\* Prior treatment with a Mitogen-Activated protein Kinase (MEK) inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable).\n\* Last radiation therapy within 4 weeks prior starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KRAS gene mutation be eligible for the clinical trial?

Answer:  
Based on the eligibility criteria provided for the clinical trial, a patient with a KRAS gene mutation would be eligible to participate, assuming they meet all other inclusion and exclusion criteria. Specifically, one of the inclusion criteria is that the patient must have a "KRAS mutation positive tumour sample as determined by the designated testing laboratory."  
  
However, it's important that the patient also:  
  
1. Provides informed consent.  
2. Is 18 years or older.  
3. Has histological or cytological confirmation of locally advanced or metastatic NSCLC (stage IIIB-IV).  
4. Has experienced failure of first-line anti-cancer therapy due to disease progression or relapse.  
  
Additionally, the patient must not meet any of the exclusion criteria, such as having mixed small cell and non-small cell lung cancer histology, having received more than one prior anti-cancer drug regimen for advanced or metastatic NSCLC, or having received certain treatments within restricted time frames before the start of the study treatment. If the patient satisfies all these conditions, they would be eligible for the trial.